Found this in the latest edition of CF Today (publication of the CF Trust). This is something different - not what is currently going through the clinical trials in the UK.
Our gene therapy programme is investigating different ways of getting the healthy copy of the gene to the cells lining the lung.Wave 1 of our research, which is the product about to start inclinical trial, will be followed by Wave 2, which we envisage willbe the next stage of gene therapy - you may remember thatwe said the first wave was going to be like the Wright brothers'first flight - it worked, but it wasn't exactly business class.Wave 1 uses a vector or delivery system which is a liposome* - Lipid 67 to be precise.The Wave 2 product, which is in development, is exploringother non-viral options, but is also looking very closely at adifferent vector - this time a virus - produced by a Japanesecompany called DNAVEC Corporation. Our Gene TherapyConsortium has long believed that viruses were unlikely to bea suitable delivery system because although they are veryeffective at getting to the lung (in fact that's what they evolvedto do), they couldn't be delivered repeatedly. However, theyseem to have found the exception that proves the rule.This viral vector seems to have the double advantage of beingcapable of repeat delivery and of lasting several months. So far,our gene therapists have conducted their research using verysmall quantities of this vector. As their findings have been veryencouraging indeed, we are keen to obtain greater amounts.We were therefore very pleased to welcome MamoruHasegawa, President and CEO of DNAVEC, and Akihiro Iida,Corporate Officer at DNAVEC, to our HQ in Bromley to meetwith us, our scientists and some of our Trustees to discuss howwe might work together in the future. The costs involved inthis product development are currently being explored, but wehope to see our way forward to progress what seems to be avery promising prospect.Pictured below are the Japanese visitors together withmembers of the UK Gene Therapy Consortium and CF Truststaff and trustees at our HQ in March.New Possibilities for Deliveryof Gene Therapy*Liposomes are fat (lipid) globules that have beenspecially manufactured to deliver substances such asmedications to cells in the body.The Cystic Fibrosis Trust recently awarded the AdultCystic Fibrosis Unit at Gartnavel General Hospital inGlasgow a grant of £50,000 to facilitate the appointmentof a new CF Consultant. The grant will be repeated forthree years bringing the total amount awarded to£150,000. The Centre cares for almost 200 adults withCystic Fibrosis in the West of Scotland.Gartnavel Grant
Our gene therapy programme is investigating different ways of getting the healthy copy of the gene to the cells lining the lung.Wave 1 of our research, which is the product about to start inclinical trial, will be followed by Wave 2, which we envisage willbe the next stage of gene therapy - you may remember thatwe said the first wave was going to be like the Wright brothers'first flight - it worked, but it wasn't exactly business class.Wave 1 uses a vector or delivery system which is a liposome* - Lipid 67 to be precise.The Wave 2 product, which is in development, is exploringother non-viral options, but is also looking very closely at adifferent vector - this time a virus - produced by a Japanesecompany called DNAVEC Corporation. Our Gene TherapyConsortium has long believed that viruses were unlikely to bea suitable delivery system because although they are veryeffective at getting to the lung (in fact that's what they evolvedto do), they couldn't be delivered repeatedly. However, theyseem to have found the exception that proves the rule.This viral vector seems to have the double advantage of beingcapable of repeat delivery and of lasting several months. So far,our gene therapists have conducted their research using verysmall quantities of this vector. As their findings have been veryencouraging indeed, we are keen to obtain greater amounts.We were therefore very pleased to welcome MamoruHasegawa, President and CEO of DNAVEC, and Akihiro Iida,Corporate Officer at DNAVEC, to our HQ in Bromley to meetwith us, our scientists and some of our Trustees to discuss howwe might work together in the future. The costs involved inthis product development are currently being explored, but wehope to see our way forward to progress what seems to be avery promising prospect.Pictured below are the Japanese visitors together withmembers of the UK Gene Therapy Consortium and CF Truststaff and trustees at our HQ in March.New Possibilities for Deliveryof Gene Therapy*Liposomes are fat (lipid) globules that have beenspecially manufactured to deliver substances such asmedications to cells in the body.The Cystic Fibrosis Trust recently awarded the AdultCystic Fibrosis Unit at Gartnavel General Hospital inGlasgow a grant of £50,000 to facilitate the appointmentof a new CF Consultant. The grant will be repeated forthree years bringing the total amount awarded to£150,000. The Centre cares for almost 200 adults withCystic Fibrosis in the West of Scotland.Gartnavel Grant